Johnson & Johnson Files NDA Seeking Accelerated Approval Of Bedaquiline In Tuberculosis
The compound, a diarylquinolone, would be the first therapy approved for TB offering a new mechanism of action in 40-plus years.
The compound, a diarylquinolone, would be the first therapy approved for TB offering a new mechanism of action in 40-plus years.